These findings might also offer a clinical opportunity for oncogenesis and anticancer treatment, as cell cycle arrest has been associated with tumorigenesis in checkpoint-compromised cells52, whereas exacerbation of TRF2-mediated telomere deprotection sensitizes cancer cells to telomere-targeting drugs. The gene discussed is TERF2; the disease is cancer.